TWI866908B - 用於治療肺部疾病的可吸入的緩釋組成物 - Google Patents

用於治療肺部疾病的可吸入的緩釋組成物 Download PDF

Info

Publication number
TWI866908B
TWI866908B TW108114188A TW108114188A TWI866908B TW I866908 B TWI866908 B TW I866908B TW 108114188 A TW108114188 A TW 108114188A TW 108114188 A TW108114188 A TW 108114188A TW I866908 B TWI866908 B TW I866908B
Authority
TW
Taiwan
Prior art keywords
indolinone
anilino
methylene
phenyl
methoxycarbonyl
Prior art date
Application number
TW108114188A
Other languages
English (en)
Chinese (zh)
Other versions
TW202011941A (zh
Inventor
基隆 洪
元成 方
曾昱程
鄭婷宇
俞宛妮
唐若心
Original Assignee
盈擘生技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 盈擘生技股份有限公司 filed Critical 盈擘生技股份有限公司
Publication of TW202011941A publication Critical patent/TW202011941A/zh
Application granted granted Critical
Publication of TWI866908B publication Critical patent/TWI866908B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW108114188A 2018-04-23 2019-04-23 用於治療肺部疾病的可吸入的緩釋組成物 TWI866908B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862661217P 2018-04-23 2018-04-23
US62/661,217 2018-04-23

Publications (2)

Publication Number Publication Date
TW202011941A TW202011941A (zh) 2020-04-01
TWI866908B true TWI866908B (zh) 2024-12-21

Family

ID=66821301

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108114188A TWI866908B (zh) 2018-04-23 2019-04-23 用於治療肺部疾病的可吸入的緩釋組成物

Country Status (12)

Country Link
US (2) US11534399B2 (https=)
EP (1) EP3784213B1 (https=)
JP (1) JP7391039B2 (https=)
KR (1) KR20210003197A (https=)
CN (1) CN112004527B (https=)
AU (1) AU2019261329B2 (https=)
BR (1) BR112020021412A8 (https=)
CA (1) CA3101102A1 (https=)
ES (1) ES2964413T3 (https=)
IL (1) IL278079B2 (https=)
TW (1) TWI866908B (https=)
WO (1) WO2019209787A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004527B (zh) 2018-04-23 2024-09-24 盈擘生技股份有限公司 用于治疗肺部疾病的可吸入脂质体缓释组合物
WO2020055713A1 (en) * 2018-09-10 2020-03-19 Taiwan Liposome Co., Ltd. Sustained-release ophthalmic pharmaceutical compositions and uses thereof
US12599557B2 (en) 2019-04-25 2026-04-14 Tlc Biopharmaceuticals, Inc. Liposomal sustained-release compositions containing a therapeutic drug and use thereof
CN114040750B (zh) * 2019-05-14 2025-11-11 盈擘生技股份有限公司 用于治疗肺部疾病的可吸入支气管扩张剂缓释组合物
TW202143949A (zh) * 2020-03-22 2021-12-01 盈擘醫藥股份有限公司 用於預防或暴露後治療感染或呼吸疾病的抗病毒組成物
CN112472791A (zh) * 2020-11-16 2021-03-12 复旦大学 CsA脂质体在制备抗SARS-CoV-2药物中的应用
CN116635009A (zh) * 2020-12-14 2023-08-22 纳米科技制药公司 用于递送抗癌剂的具有改进的治疗指数的组合物和方法
CN114642656B8 (zh) * 2020-12-18 2025-12-12 盈科瑞（天津）创新医药研究有限公司 一种吸入用尼达尼布溶液及其制备方法
WO2023022520A1 (ko) * 2021-08-18 2023-02-23 주식회사 삼양홀딩스 룩소리티닙의 경구용 정제 조성물 및 이의 제조 방법
KR102348901B1 (ko) * 2021-08-26 2022-01-07 충북대학교 산학협력단 레고라페닙을 유효성분으로 포함하는 만성폐쇄성 폐질환의 예방 또는 치료용 조성물
CN116064394A (zh) * 2021-11-01 2023-05-05 中国医学科学院医药生物技术研究所 肿瘤细胞外泌体与脂质体的杂化外泌体、其制备方法及其抗肿瘤用途
JP2025069482A (ja) * 2022-03-25 2025-05-01 国立研究開発法人医薬基盤・健康・栄養研究所 特発性肺線維症の治療または予防剤
TW202415382A (zh) * 2022-09-30 2024-04-16 大陸商上海濟煜醫藥科技有限公司 脂質體藥物組合物及其製備方法和用途
BE1031669B1 (fr) * 2023-06-02 2025-01-14 Inhatarget Therapeutics Composition pharmaceutique pour inhalation
EP4637764A1 (en) * 2023-12-22 2025-10-29 Zedira GmbH Oxo-pyridine derivatives as inhibitors of transglutaminases for use in the treatment of pulmonary fibrosis
WO2025138298A1 (zh) * 2023-12-30 2025-07-03 北京睿创康泰医药研究院有限公司 一种尼达尼布超分子复合体的药物组合物
CN117899020A (zh) * 2024-01-16 2024-04-19 中山大学 一种载抗生素黏液渗透型脂质体粉雾剂的制备方法及其应用
CN118948812A (zh) * 2024-08-06 2024-11-15 北京悦康科创医药科技股份有限公司 一种多肽脂质体吸入剂及其制备方法和应用
KR102859152B1 (ko) * 2024-10-24 2025-09-12 주식회사 한국리포좀 합성 지질 리포좀 기반의 일본 뇌염 바이러스 백신 및 그의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239652A1 (en) * 2007-09-28 2010-09-23 Universitatsspital Basel Immunoliposomes for treatment of cancer
US20150044288A1 (en) * 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US20180098945A1 (en) * 2016-01-08 2018-04-12 The Regents Of The University Of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3686025T2 (de) 1985-05-22 1993-01-07 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
IE63869B1 (en) 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
US5958378A (en) 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
GB9912639D0 (en) 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
DE10214983A1 (de) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
EP1581236B1 (en) 2002-10-29 2013-10-16 Insmed Incorporated Sustained release of antiinfectives
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
KR20060015265A (ko) * 2003-05-30 2006-02-16 알자 코포레이션 제제의 폐 투여 방법
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based compositions of antiinfectives for treating pulmonary infections
US8071127B2 (en) 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
WO2012027727A2 (en) * 2010-08-26 2012-03-01 Kunyuan Cui Lipomacrocycles and uses thereof
WO2012031603A2 (en) 2010-09-09 2012-03-15 Danish Medical Consults Aps Airway administration of angiogenesis inhibitors
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
EP4309657A3 (en) * 2013-02-01 2024-02-28 Celator Pharmaceuticals, Inc. Remote loading of sparingly water-soluble drugs into liposomes
KR20150026613A (ko) * 2013-09-03 2015-03-11 삼성전자주식회사 소수성 물질 및 조영제를 포함하는 리포좀 및 그의 용도
NZ760541A (en) 2014-01-10 2022-08-26 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2016090111A1 (en) 2014-12-05 2016-06-09 Vindico NanoBio Technology Inc. Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
US20180344644A1 (en) * 2015-09-21 2018-12-06 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
CA3013768A1 (en) * 2016-02-04 2017-08-10 Stem Cell Theranostics, Inc. Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
CN112004527B (zh) 2018-04-23 2024-09-24 盈擘生技股份有限公司 用于治疗肺部疾病的可吸入脂质体缓释组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239652A1 (en) * 2007-09-28 2010-09-23 Universitatsspital Basel Immunoliposomes for treatment of cancer
US20150044288A1 (en) * 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US20180098945A1 (en) * 2016-01-08 2018-04-12 The Regents Of The University Of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery

Also Published As

Publication number Publication date
TW202011941A (zh) 2020-04-01
KR20210003197A (ko) 2021-01-11
CA3101102A1 (en) 2019-10-31
JP2021522163A (ja) 2021-08-30
ES2964413T3 (es) 2024-04-05
WO2019209787A1 (en) 2019-10-31
IL278079B2 (en) 2025-08-01
BR112020021412A2 (pt) 2021-01-19
BR112020021412A8 (pt) 2022-07-05
US20230088661A1 (en) 2023-03-23
US11534399B2 (en) 2022-12-27
IL278079A (en) 2020-11-30
EP3784213B1 (en) 2023-09-06
CN112004527B (zh) 2024-09-24
US12533313B2 (en) 2026-01-27
EP3784213A1 (en) 2021-03-03
IL278079B1 (en) 2025-04-01
EP3784213C0 (en) 2023-09-06
CN112004527A (zh) 2020-11-27
JP7391039B2 (ja) 2023-12-04
AU2019261329A1 (en) 2020-11-12
US20210145740A1 (en) 2021-05-20
AU2019261329B2 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
TWI866908B (zh) 用於治療肺部疾病的可吸入的緩釋組成物
JP4885715B2 (ja) イリノテカン製剤
JP2021522163A5 (https=)
CN116635009A (zh) 用于递送抗癌剂的具有改进的治疗指数的组合物和方法
US12447163B2 (en) Liposomal formulations of Bcl inhibitors
JP4874097B2 (ja) 水難溶性カンプトテシン含有リポソーム製剤
TWI757739B (zh) 包含弱酸藥物之醫藥組成物及其用途
TWI853932B (zh) 用於治療肺部疾病之可吸入的支氣管擴張劑緩釋組成物
HK40043569A (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases
HK40043569B (zh) 用於治疗肺部疾病的可吸入脂质体缓释组合物
JP2012236772A (ja) スピカマイシン誘導体を有するリポソーム製剤
JP2024526800A (ja) Ｂｃｌ阻害剤のリポソーム製剤
CN120837450A (zh) 脂质纳米颗粒制剂
HK40128812A (zh) 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法
HK40066938A (zh) 用於治疗肺部疾病的可吸入支气管扩张剂缓释组合物
HK40102572A (zh) 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法
HK40066938B (zh) 用於治疗肺部疾病的可吸入支气管扩张剂缓释组合物